Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
MATINAS BIOPHARMA HOLDINGS I (MTNB) Stock Price & Overview
NYSEARCA:MTNB • US5768103039
Current stock price
0.699 USD
+0.05 (+7.47%)
At close:
0.6601 USD
-0.04 (-5.57%)
After Hours:
The current stock price of MTNB is 0.699 USD. Today MTNB is up by 7.47%. In the past month the price increased by 27.9%. In the past year, price increased by 14.59%.
MTNB Key Statistics
52-Week Range0.48 - 3.09
Current MTNB stock price positioned within its 52-week range.
1-Month Range0.48 - 0.699
Current MTNB stock price positioned within its 1-month range.
- Market Cap
- 4.481M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.17
- Dividend Yield
- N/A
MTNB Stock Performance
Today
+7.47%
1 Week
+14.59%
1 Month
+27.90%
3 Months
+16.93%
Longer-term
6 Months -49.35%
1 Year +14.59%
2 Years -91.46%
3 Years -96.35%
5 Years -98.18%
10 Years N/A
MTNB Stock Chart
MTNB Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to MTNB. When comparing the yearly performance of all stocks, MTNB is one of the better performing stocks in the market, outperforming 70.09% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
MTNB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to MTNB. MTNB may be in some trouble as it scores bad on both profitability and health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
MTNB Earnings
Next Earnings DateMay 13, 2026
Last Earnings DateMar 31, 2026
PeriodQ4 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %
MTNB Forecast & Estimates
Analysts
Analysts45.71
Price TargetN/A
EPS Next Y63.31%
Revenue Next YearN/A
MTNB Financial Highlights
Over the last trailing twelve months MTNB reported a non-GAAP Earnings per Share(EPS) of -4.17. The EPS increased by 24.18% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-24.25M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -336.45% | ||
| ROE | -502.09% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%81.64%
Sales Q2Q%N/A
EPS 1Y (TTM)24.18%
Revenue 1Y (TTM)-100%
MTNB Ownership
Ownership
Inst Owners7.06%
Shares6.41M
Float4.99M
Ins Owners8.67%
Short Float %0.07%
Short Ratio0.14
MTNB Industry Overview
MTNB operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.2
MTNB Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MTNB
Company Profile
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Bedminster, New Jersey and currently employs 3 full-time employees. The company went IPO on 2014-06-03. The firm is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.
Company Info
IPO: 2014-06-03
MATINAS BIOPHARMA HOLDINGS I
Suite 302, 1545 Route 206 South
Bedminster NEW JERSEY 07921 US
CEO: Jerome D. Jabbour
Employees: 3
Phone: 19084431860
MATINAS BIOPHARMA HOLDINGS I / MTNB FAQ
Can you describe the business of MATINAS BIOPHARMA HOLDINGS I?
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Bedminster, New Jersey and currently employs 3 full-time employees. The company went IPO on 2014-06-03. The firm is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.
Can you provide the latest stock price for MATINAS BIOPHARMA HOLDINGS I?
The current stock price of MTNB is 0.699 USD. The price increased by 7.47% in the last trading session.
Does MTNB stock pay dividends?
MTNB does not pay a dividend.
What is the ChartMill rating of MATINAS BIOPHARMA HOLDINGS I stock?
MTNB has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Would investing in MATINAS BIOPHARMA HOLDINGS I be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MTNB.
What is the market capitalization of MTNB stock?
MATINAS BIOPHARMA HOLDINGS I (MTNB) has a market capitalization of 4.48M USD. This makes MTNB a Nano Cap stock.
Can you provide the upcoming earnings date for MATINAS BIOPHARMA HOLDINGS I?
MATINAS BIOPHARMA HOLDINGS I (MTNB) will report earnings on 2026-05-13.